What changed

A jar promise for the face is not what this paper measured.

Last updated 2026-09-18

Short-term topical estradiol raised collagen markers on sun-protected hip skin, but not on photoaged face or forearm. A jar promise for the face is not what this paper measured.

The mechanism, in plain language

Short-term topical estradiol raised collagen markers on sun-protected hip skin, but not on photoaged face or forearm in that study, so a jar promise for the face is not what this paper measured. That is a short-term, vehicle-controlled topical estradiol study in older adults. Not a retail anti-aging cream trial. Not proof that a jar rebuilds facial collagen.

Rittié et al. (Archives of Dermatology, 2008) applied topical estradiol for 2 weeks in about 40 postmenopausal women and 30 men, mean age about 75. On sun-protected hip skin, procollagen I and III mRNA and collagen I protein increased. On photoaged face and forearm, there was no significant collagen induction, even though estrogen receptors and a GREB1 response were present at those sites. Hip is not face. Hip is not forearm.

A separate open study of early postmenopausal women found that about 1 year (about 12 months) of systemic estrogen alone or with progestin did not change the skin collagen parameters those authors measured. That is balance honesty, not a face-jar claim.

Laparotomy-skin collagen (Affinito complement)

Laparotomy-skin collagen percentages fell with years since menopause in this biopsy study.

In laparotomy-skin biopsies performed during laparotomic operation, postmenopausal women had lower type I and type III collagen percentages than premenopausal women, with an inverse link to years since menopause. That is laparotomy-skin histology from surgery, not a face jar trial and not an OTC anti-aging test.

This card sits beside the brakes already on this moment. Short-term topical estradiol raised collagen markers on sun-protected hip skin, but not on photoaged face or forearm in that study. A separate open systemic year showed no change on the collagen parameters those authors measured. Affinito does not replace those brakes. It adds histology of laparotomy skin taken during laparotomic operation.

Honesty limits

This page explains papers. It does not tell you what your skin is doing.

• Primary brake: Rittié et al. 2008. Topical estradiol for 2 weeks. About 40 postmenopausal women and 30 men. Mean age about 75. Vehicle-controlled. Older adults. Not a retail jar trial.
• Hip (sun-protected): procollagen I and III mRNA and collagen I protein increased. Do not invent a hip fold-change percent from press summaries.
• Photoaged face and forearm: no significant collagen induction, despite estrogen receptors and GREB1 response at those sites. Site contrast is the point.
• Haapasaari et al. 1997. Maturitas. Open, non-randomized. Early post-menopause. About 43 women. About 1 year (about 12 months) of systemic estrogen alone or with progestin: null on the collagen parameters studied.
• Topical estradiol here is medical information only. Never a product call to action. Never an HRT start or stop instruction. Never a recommendation to use topical estrogen for facial anti-aging.
• No cream sold on MenoDerm. Chinese wall versus SisLuna. No Shop.
• Affinito complement: Affinito et al. 1999. Maturitas. n=32 (14 premenopausal, 18 postmenopausal). Mean age 48.78±9.86 (range 28-68).
• Site: biopsies performed during laparotomic operation. Laparotomy-skin. Not face.
• Immunohistochemistry and computerised image analysis: lower percentages of type I, type III, and the type III/I ratio after menopause (P<0.01).
• Inverse link to years since menopause for those percentages in postmenopausal women. Direction first. The abstract pairs the word inverse with positive r values (r = 0.76, 0.73, and 0.73; P<0.01). Full-text sign convention is not verified.
• Authors suggest the decrease is estrogen-related. Medical information only. Never an HRT start or stop instruction. Never a product call to action.
• Did not test OTC anti-aging actives. No jar claim from this paper. Do not invent a fold-change percent. The abstract gives direction, not a headline percentage.

Thigh skin collagen fell with years since menopause in the 1987 untreated group; the 1985 work tracked menopausal age, and implant-treated groups looked different.

In untreated women in the 1987 work, thigh skin collagen fell with years since menopause, and in the earlier 1985 study skin collagen declined with menopausal age more than chronological age; implant-treated groups did not show the same decline and had greater skin collagen and thickness. That is implant-era structure work (1987 thigh; 1985 site unnamed in the abstract), not a face jar trial and not a retail cream claim.

This card sits beside the LIVE brakes and the Affinito body-wall histology complement. Short-term topical estradiol raised collagen markers on sun-protected hip skin, but not on photoaged face or forearm in that study. A separate open systemic year showed no change on the collagen parameters those authors measured. Affinito adds laparotomy-skin type I and III percentages. Brincat does not replace those cards. It adds classic implant-era structure findings (1987 thigh; 1985 site unnamed).

Honesty limits (Brincat)

• Brincat et al. 1987. BJOG. Thigh skin collagen. 69 untreated postmenopausal women; 37 on oestradiol and testosterone implants for 2 to 10 years.
• Untreated: thigh collagen fell with years since menopause. Authors say the decrease was preventable in the implant-treated group.
• Brincat et al. 1985. BJOG. Sex hormone implants versus untreated. Treated: greater skin collagen and thickness. Untreated: collagen declined with menopausal age, not chronological age. Abstract does not give n or name the biopsy site.
• Observational plus treated comparator. 1980s methods. Not a face jar RCT. Not OTC actives.
• Implant regimens are medical information only. Never an HRT start/stop instruction. Never a cream claim.
• Do not invent a fold-change percent or a 1985 sample size from the abstract.
• No cream sold on MenoDerm. Chinese wall versus SisLuna.

Rittié L et al. Arch Dermatol. 2008;144:1129-1140. doi:10.1001/archderm.144.9.1129

Haapasaari K-M et al. Maturitas. 1997;27:153-162. doi:10.1016/s0378-5122(97)01128-6

Affinito P, Palomba S, Sorrentino C, Di Carlo C, Bifulco G, Arienzo MP, Nappi C. Maturitas. 1999;33:239-247. doi:10.1016/s0378-5122(99)00077-8

Brincat M, Moniz CJ, Studd JW, Darby A, Magos A, Emburey G, Versi E. Br J Obstet Gynaecol. 1985;92:256-259. doi:10.1111/j.1471-0528.1985.tb01091.x

Brincat M, Moniz CF, Kabalan S, Versi E, O’Dowd T, Magos AL, Montgomery J, Studd JW. Br J Obstet Gynaecol. 1987;94:126-129. doi:10.1111/j.1471-0528.1987.tb02338.x

Maheux 1994 + Dunn 1997 (careful secondary)

A body-site HRT RCT thickened skin on ultrasound and biopsy; a large survey linked estrogen use to lower odds of dry skin and wrinkling on exam.

In a 12-month RCT of 60 postmenopausal women, oral conjugated estrogens increased ultrasound skin thickness (p < 0.01) and dermal thickness on biopsy (p < 0.05) at the right great trochanter versus placebo. Separately, a cross-sectional NHANES I survey of 3875 postmenopausal women associated estrogen use with lower odds of senile dry skin (OR 0.76; 0.60-0.97) and wrinkling (OR 0.68; 0.52-0.89) on dermatologist exam, and not with atrophy. That is association, not a prescription trial, and not a cream-sits claim. Medical information for clinician conversation only; never an HRT CTA and never a Shop pitch.

This card sits beside the LIVE brakes and the Affinito / Brincat structure neighbors. Short-term topical estradiol raised collagen markers on sun-protected hip skin, but not on photoaged face or forearm in that study. A separate open systemic year showed no change on the collagen parameters those authors measured. Maheux and Dunn do not replace those cards. They add a systemic conjugated-estrogens thickness RCT at a body site and an epidemiologic association on dryness and wrinkling.

Honesty limits (Maheux + Dunn)

• Maheux et al. 1994. Am J Obstet Gynecol. 60 postmenopausal women. Double-blind conjugated estrogens versus placebo for 12 months. Right great trochanter (body site, not face). Ultrasound skin thickness up (p < 0.01); dermis up on biopsy (p < 0.05). Placebo: no significant change. Dose in milligrams is not in the abstract. Do not invent a thickness percent.
• Dunn et al. 1997. Arch Dermatol. NHANES I. Cross-sectional. 3875 postmenopausal women (hormone-use data for 3403; 88%). Self-report noncontraceptive estrogen. Dermatologist surface exam. Senile dry skin OR 0.76 (0.60-0.97); wrinkling OR 0.68 (0.52-0.89); smoking-adjusted wrinkling OR 0.67 (0.44-1.01; CI includes 1.0); not associated with atrophy. Association only. Design critique companion: Arch Dermatol. 1997;133:1460-1462.
• Not a face jar RCT. Not OTC actives. Not TEWL or ceramides. Not cream-sits.
• Systemic conjugated estrogens and estrogen-use associations are medical information only. Never an HRT start/stop instruction. Never a cream claim.
• Do not invent a Maheux dose or thickness percent from the abstract. Do not copy Dunn authors’ causal “prevents” wording into consumer lines.
• No cream sold on MenoDerm. Chinese wall versus SisLuna.

Maheux R, Naud F, Rioux M, Grenier R, Lemay A, Guy J, Langevin M. Am J Obstet Gynecol. 1994;170:642-649. doi:10.1016/s0002-9378(94)70242-x

Dunn LB, Damesyn M, Moore AA, Reuben DB, Greendale GA. Arch Dermatol. 1997;133:339-342. doi:10.1001/archderm.133.3.339

Estrogen, skin aging, and study design. Arch Dermatol. 1997;133:1460-1462.

Source rules